Company Quick10K Filing
Creative Medical Technology
Price-0.00 EPS-0
Shares2,108 P/E0
MCap-0 P/FCF0
Net Debt1 EBIT-2
TEV1 TEV/EBIT-1
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-04-06
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-13
10-Q 2019-03-31 Filed 2019-05-20
10-K 2018-12-31 Filed 2019-04-01
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-21
10-K 2017-12-31 Filed 2018-03-29
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-10
10-K 2016-12-31 Filed 2017-02-13
10-Q 2016-09-30 Filed 2016-11-10
10-Q 2016-06-30 Filed 2016-08-19
10-Q 2016-03-31 Filed 2016-05-13
10-K 2015-12-31 Filed 2016-04-14
10-Q 2015-09-30 Filed 2015-11-09
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-08
10-K 2014-12-31 Filed 2015-02-27
10-Q 2014-09-30 Filed 2014-11-12
10-Q 2014-06-30 Filed 2014-08-08
10-Q 2014-03-31 Filed 2014-05-13
10-K 2013-12-31 Filed 2014-03-17
10-Q 2013-09-30 Filed 2013-11-13
10-Q 2013-06-30 Filed 2013-08-07
10-Q 2013-03-31 Filed 2013-05-07
10-K 2012-12-31 Filed 2013-03-15
10-Q 2012-09-30 Filed 2012-11-07
10-Q 2012-06-30 Filed 2012-08-09
10-Q 2012-03-31 Filed 2012-05-11
10-K 2011-12-31 Filed 2012-03-26
10-Q 2011-09-30 Filed 2011-10-31
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-03-31
10-Q 2010-09-30 Filed 2010-10-19
10-Q 2010-06-30 Filed 2010-08-12
10-Q 2010-03-31 Filed 2010-05-07
10-K 2009-12-31 Filed 2010-02-03
8-K 2020-03-19
8-K 2020-01-28
8-K 2019-10-11
8-K 2019-09-04
8-K 2019-07-24
8-K 2019-07-02
8-K 2019-06-20
8-K 2019-04-30
8-K 2019-03-28
8-K 2019-02-28
8-K 2019-02-12
8-K 2018-12-27
8-K 2018-11-21
8-K 2018-11-06
8-K 2018-10-17
8-K 2018-09-20
8-K 2018-08-14
8-K 2018-08-08
8-K 2018-07-19
8-K 2018-07-06
8-K 2018-06-19
8-K 2018-05-23
8-K 2018-05-08
8-K 2018-04-30
8-K 2018-04-26
8-K 2018-04-26
8-K 2018-04-12
8-K 2018-04-11
8-K 2018-03-26
8-K 2018-03-15
8-K 2018-02-22
8-K 2018-02-01
8-K 2018-01-12
8-K 2018-01-09
8-K 2018-01-05
8-K 2017-12-29

CELZ 10Q Quarterly Report

Note 1 - Organization and Summary of Significant Accounting Policies
Note 2 - Licensing Agreements
Note 3 - Related Party Transactions
Note 4 - Debt
Note 5 - Derivative Liabilities
Note 6 - Warrants
Note 7 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 6. Exhibits
EX-31.1 tm2014547d1_ex31-1.htm
EX-31.2 tm2014547d1_ex31-2.htm
EX-32.1 tm2014547d1_ex32-1.htm
EX-32.2 tm2014547d1_ex32-2.htm

Creative Medical Technology Earnings 2020-03-31

Balance SheetIncome StatementCash Flow
0.6-1.5-3.6-5.8-7.9-10.02012201420172020
Assets, Equity
0.1-1.9-3.9-6.0-8.0-10.02012201420172020
Rev, G Profit, Net Income
0.50.30.1-0.0-0.2-0.42012201420172020
Ops, Inv, Fin

10-Q 1 tm2014547d1_10q.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

Or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission File Number: 000-53500

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   87-0622284
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
3008 W. Lupine, Phoenix, AZ   85029
(Address of principal executive offices)   (Zip Code)

 

(833) 336-7636

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports).

Yes x No ¨

 

Indicate by check mark whether the registrant has been subject to such filing requirements for the past 90 days.

Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer x Smaller reporting company x
    Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

 

The number of shares outstanding of the registrant’s common stock on May 11, 2020, was 144,855,448.

  

 

  

 

 

 

  Page Number
PART I – FINANCIAL INFORMATION
   
Item 1. Financial Statements
     
  Unaudited Condensed Consolidated Balance Sheet 3
     
  Unaudited Condensed Consolidated Statement of Operations 4
     
  Unaudited Condensed Consolidated Statements of Cash Flows 5
     
  Unaudited Condensed Consolidated Statement of Stockholder' (deficit) 6
     
  Notes to Unaudited Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 14
     
Item 4. Controls and Procedures 14
   
PART II – OTHER INFORMATION 15
   
Item 1. Legal Proceedings 15
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
     
Item 6. Exhibits 15

 

2 

 

   

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31, 2020   December 31, 2019 
ASSETS          
CURRENT ASSETS          
Cash  $38,327   $88,648 
Accounts receivable   8,400    5,600 
Inventory   2,800    - 
Total Current Assets   49,527    94,248 
           
OTHER ASSETS          
Licenses, net of amortization   419,783    436,555 
TOTAL ASSETS  $469,310   $530,803 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable  $386,565   $320,785 
Accrued expenses   137,574    120,492 
Management fee and patent liability - related party   244,345    240,082 
Convertible notes payable, net of discount of $439,374 and $560,899, respectively   1,031,360    1,062,266 
Advances from related party   10,800    10,800 
Derivative liabilities   1,840,921    6,847,877 
Total Current Liabilities   3,651,565    8,602,302 
           
TOTAL LIABILITIES   3,651,565    8,602,302 
           
Commitments and contingencies          
           
STOCKHOLDERS' DEFICIT          
Preferred stock, $0.001 par value, 7,000,000 and 7,000,000 shares authorized, no shares issued and outstanding at March 31, 2020 and December 31, 2019   -    - 
Series A preferred stock, $0.001 par value, 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at March 31, 2020 and December 31, 2019   3,000    3,000 
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 85,760,727 and 22,493,046 issued and 85,756,727 and 22,489,046 outstanding at March 31, 2020 and December 31, 2019, respectively   85,757    22,489 
Additional paid-in capital   18,551,514    17,468,018 
Accumulated deficit   (21,822,526)   (25,565,006)
TOTAL STOCKHOLDERS' DEFICIT   (3,182,255)   (8,071,499)
           
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $469,310   $530,803 

    

The accompanying notes are an integral part of these condensed consolidated financial statements      

 

3 

 

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

 

    For the Three
Months Ended
March 31, 2020
    For the Three
Months Ended
March 31, 2019
 
             
Revenues   $ 42,100     $ 50,800  
                 
Cost of revenues     14,196       14,239  
                 
Gross profit     27,904       36,561  
                 
OPERATING EXPENSES                
Selling, general and administrative     346,168       281,974  
Amortization of patent costs     16,772       5,286  
TOTAL EXPENSES     362,940       287,260  
                 
Operating loss     (335,036 )     (250,699 )
                 
OTHER INCOME/(EXPENSE)                
Interest expense     (323,223 )     (454,542 )
Loss on extinguishment of convertible notes     -       (357,292 )
Change in fair value of derivatives liabilities     4,400,739       265,167  
Total other income (expense)     4,077,516       (546,667 )
                 
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES     3,742,480       (797,366 )
                 
Provision for income taxes     -       -  
                 
NET INCOME (LOSS)   $ 3,742,480     $ (797,366 )
                 
BASIC NET INCOME (LOSS) PER SHARE   $ 0.09     $ (0.12 )
                 
DILUTED NET INCOME (LOSS) PER SHARE   $ 0.00     $ (0.12 )
                 
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC     40,746,192       6,437,865  
                 
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED     776,604,919       6,437,865  

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

4 

 

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

   For the Three
Months Ended
March 31, 2020
   For the Three
Months Ended
March 31, 2019
 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $3,742,480   $(797,366)
Adjustments to reconcile net income (loss) to net cash from operating activities:          
Amortization   16,772    5,286 
Amortization of debt discounts   289,825    396,240 
Change in fair value of derivatives liabilities   (4,400,739)   (265,167)
Loss on extinguishment of convertible notes payable        357,292 
Changes in assets and liabilities:          
Accounts receivable   (2,800)   9,437 
Inventory   (2,800)   - 
Accounts payable   65,780    10,961 
Accrued expenses   46,898    55,302 
Management fee payable   49,263    (45,000)
Net cash used in operating activities   (195,321)   (273,015)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payments on convertible notes payable   -    (168,300)
Prepayment premiums paid on convertible notes payable   -    (19,154)
Proceeds from convertible notes payable   145,000    575,890 
Net cash provided from financing activities   145,000    388,436 
           
NET INCREASE (DECREASE) IN CASH   (50,321)   115,421 
BEGINNING CASH BALANCE   88,648    304,056 
ENDING CASH BALANCE  $38,327   $419,477 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash payments for interest  $6,000   $2,357 
Cash payments for income taxes  $-   $- 
           
NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Conversion of notes payable, accrued interest and derivative liabilities into common stock  $1,101,764   $1,187,223 
Conversion of management fees and patent liability into common stock  $45,000   $- 
Discounts on convertible notes due to derivative liabilities  $145,000   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.    

  

5 

 

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

                              

                   Total 
   Series A Preferred Stock   Common Stock   Additional   Accumulated   Stockholders' 
   Shares   Amount   Shares   Amount   Paid-in Capital   Deficit   Deficit 
December 31, 2019   3,000,000   $3,000    22,489,046   $22,489   $17,468,018   $(25,565,006)  $(8,071,499)
                                    
Common stock issued for related party management liabilities   -    -    2,250,000    2,250    42,750    -    45,000 
                                    
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities   -     4547-     61,016,388    61,016    289,531    -    350,547 
                                    
Relief of derivative liabilities   -    -    -    -    751,217    -    751,217 
                                    
Difference in shares from reverse stock split   -    -    1,293    2    (2)   -    - 
                                    
Net income   -    -    -    -    -    3,742,480    3,742,480 
                                    
March 31, 2020   3,000,000   $3,000    85,756,727   $85,757   $18,551,514   $(21,822,526)  $(3,182,255)

                         

                   Total 
   Series A Preferred Stock   Common Stock   Additional   Accumulated   Stockholders'  
   Shares   Amount   Shares   Amount   Paid-in Capital   Deficit   Deficit 
December 31, 2018   3,000,000   $3,000    6,018,075   $6,018   $13,077,678   $(17,081,333)  $(3,994,637)
                                    
Common stock issued for cashless warrant exercise   -    -    474,486    474    (474)   -    - 
                                    
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities   -    -    224,029    225    168,750    -    168,975 
                                    
Relief of derivative liabilities   -    -    -    -    1,018,248    -    1,018,248 
                                    
Net loss   -    -    -    -    -    (797,366)   (797,366)
                                    
March 31, 2019   3,000,000   $3,000    6,716,590   $6,717   $14,264,202   $(17,878,699)  $(3,604,780)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

6 

 

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2020

 

Introductory Comment

 

Unless otherwise indicated, any reference to “our company”, “we”, “us”, or “our” refers to Creative Medical Technology Holdings, Inc., and as applicable to its wholly owned subsidiary, Creative Medical Technologies, Inc., a Nevada corporation (“CMT”).

 

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization - Creative Medical Technology Holdings, Inc., is considered to be a commercial stage company, following the commencement of sales of disposable kits used in our Caverstem® procedure to treat ED in the fourth quarter of 2017 and sales of our FemCelz procedure for vaginal rejuvenation that commenced in the second quarter of 2019. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell product, purchased the patent for our ED and lower back pain procedures, and filed patent applications for our other urological and neurological treatments.

  

Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2020 and for the three-month period then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three-month period ended March 31, 2020, are not necessarily indicative of the operating results for the full year.

 

Going Concern – The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the three-month period ended March 31, 2020, the Company had negative cash flows from operating activities of $195,321 and had a working capital deficit of $3,602,038. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

Risks and Uncertainties - On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

 

Revenue - We have adopted the new revenue recognition standards that went into effect on January 1, 2019. All revenues reported in 2019 and beyond reflect those standards. Adoption of the standards had no effect on the Company’s revenues.

  

Fair Value of Financial Instruments   - The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables.  The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

  

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2020, and December 31, 2019, the Company didn’t have any Level 1 or 2 financial instruments. The table below reflects the results of our Level 3 fair value calculations:

 

   Notes   Warrants   Total 
Derivative liability at December 31, 2019  $6,659,055   $188,822   $6,847,877 
Addition of new conversion option derivatives   286,409    -    286,409 
Extinguishment/modification        -    - 
Conversion of note derivatives   (751,217)   -    (751,217)
Change in fair value   (4,397,140)   (145,008)   (4,542,148)
Derivative liability at March 31, 2020  $1,797,107   $43,814   $1,840,921 

 

7 

 

 

Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

 

The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the three months ended March 31, 2020.

 

   For the Three
Months Ended
March 31, 2020
 
Weighted average common shares outstanding used in calculating basic earnings per share   40,746,192 
Effect of warrants   4,834,433 
Effect of convertible notes payable   562,263,144 
Effect of convertible related party management fee and patent liabilities   168,761,150 
Weighted average common shares outstanding used in calculating diluted earnings per share   776,604,919 
      
Net income as reported  $3,742,480 
Add - Interest on convertible notes payable   49,714 
Net income available to common stockholders  $3,792,194 

 

The Company excluded 3,333 options and 209,827 warrants from the computation of diluted net income per share for the three months ended March 31, 2020 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.

 

At March 31, 2019, the Company had various convertible notes payable convertible into approximately 2,610,764 shares of common stock. During the three-month period ended March 31, 2019, the Company had 3,333 options and 427,761 warrants to purchase common stock outstanding. The effects of the dilutive securities were anti-dilutive due to net loss during the three-month period ended March 31, 2019.

 

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

 

NOTE 2 – LICENSING AGREEMENTS

 

ED Patent – The Company acquired a patent from CMH. Amortization expense of $2,493 was recorded for the three-month periods ended March 31, 2020 and 2019. As of March 31, 2020 and December 31, 2019, the carrying value of the patent was $58,439 and $60,932, respectively. The Company expects to amortize approximately $9,972 annually through 2026 related to the patent costs.

 

Multipotent Amniotic Fetal Stem Cells License Agreement - In August 2016, CMT entered into a License Agreement with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of March 31, 2020 and December 31, 2019, no amounts are currently due to the University.

 

8 

 

 

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $294 was recorded for the three-month periods ended March 31, 2020 and 2019. As of March 31, 2020 and December 31, 2019, the carrying value of the patent was $6,135 and $6,429, respectively. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.

 

Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

 

·The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
·In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

 

o$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
o$200,000, upon completion of the IRB clinical trial.
o$300,00 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

  

·In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

 

o$100,000 upon filing an IND with the FDA.
o$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
o$400,000 upon dosing the first patient in a Phase 3 clinical trial.

  

·Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.
·In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.
·For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

 

The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $2,500 was recorded for the three-month periods ended March 31, 2020 and 2019. As of March 31, 2020 and December 31, 2019, the carrying value of the initial patent license was $72,500 and $75,000, respectively. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

 

In November, 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 was recorded for the three-month period ended March 31, 2020. As of March 31, 2020 and December 31, 2019, the carrying value of the patent was $282,709 and $294,194, respectively. The Company expect to amortize approximately $46,000 annually through 2027 related to the patent costs

   

NOTE 3 – RELATED PARTY TRANSACTIONS

 

The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2019. Each of the Company’s executive officers is employed by CMH, and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. During the three months ended March 31, 2020 and 2019, the Company recorded $135,000 in expense in connection with this agreement.

 

9 

 

 

As of March 31, 2020 and December 31, 2019, amounts due to CMH under the arrangement were $4,345 and $82, respectively..

 

See Note 2 for discussion of an additional related party transaction with CMH.

 

NOTE 4 – DEBT

  

During the three months ended March 31, 2020, we issued $168,300 in convertible notes to accredited investors with net proceeds of $145,000. The notes mature during February of 2021 and bear interest at rate of 8%. The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is amortizing the discount due to derivative liabilities and on-issuance discount totalling $168,300 to interest expense using the straight-line method over the original terms of the loans.

 

During the three months ended March 31, 2020 and 2019, the Company amortized $289,825 and $396,240, respectively, to interest expense. As of March 31, 2020, total discounts of $439,374 remained for which will be expensed through February 2021.

 

During the three months ended March 31, 2020, the Company issued an aggregate of 61,016,388 shares upon the conversion of $350,547 of outstanding principal, interest and fees on existing, outstanding notes.  During the three months ended March 31, 2019, the Company issued an aggregate of 224,029 shares upon the conversion of $168,975 of outstanding principal, interest and fees on existing, outstanding notes and 474,486 shares upon the cashless exercise of 527,384 warrants.

 

During the three months ended March 31, 2020, the Company incurred no pre-payment premiums as there was extinguishment of principal. During the three months ended March 31, 2019, the Company incurred $19,154 in pre-payment premiums associated with the extinguishment of $168,300 in principal that was recorded as interest expense.

 

As of March 31, 2020, future loan maturities are as follows:

  

For the year ended December 31,    
     
2020   1,302,434 
2021   168,300 
Total  $1,470,734 

 

NOTE 5 – DERIVATIVE LIABILITIES

 

Derivative Liabilities

 

In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the three-months ended March 31, 2020, the Company recorded initial derivative liabilities of $286,409 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0071 to $0.0158 our stock price on the date of grant of $0.0115 to $0.0365, expected dividend yield of 0%, expected volatility of 103.96%, risk free interest rate of 1.62%  and expected terms 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $141,409, which was recorded as a day one loss in derivative liability.

 

On March 31, 2020, the derivative liabilities were revalued at $1,840,921 resulting in a gain of $4,542,148 related to the change in fair market value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.0025 to $3.0900 , our stock price on the date of valuation ($0.0045), expected dividend yield of 0%, expected volatility of 95% to 117%, risk-free interest rate of 1.62%, and an expected terms ranging from 0.5 to 4.3 years.

 

In connection with convertible notes converted, as disclosed in Note 4, the Company reclassed derivative liabilities with a fair value of $751,217 to additional paid-in capital for the three-month period ended March 31, 2020. The Company revalued the derivative liabilities at each conversion date recording the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted to the pre-conversion carrying value to additional paid-in capital.

  

10 

 

 

Future Potential Dilution

 

Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of March 31, 2020, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 589 million shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

  

NOTE 6 – WARRANTS

 

From January 2020 through March 2020, the Company issued 0 warrants.

 

The fair value of each warrant is estimated using the Black-Scholes valuation model. Assumptions used in calculating the fair value at March 31, 2020 were as follows:

 

    Weighted
Average
Inputs Used
 
       
Annual dividend yield   $ -  
Expected life (years)     2.3 to 4.3  
Risk-free interest rate     1.62 %
Expected volatility     95 to 99 %
Common stock price   $ 0.0045  

  

Since the expected life of the warrants was greater than the Company’s historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies.

 

The issuances, exercises and pricing re-sets during the three months ended March 31, 2020, are as follows:

 

Outstanding at December 31, 2019     5,044,260  
Issuances     -  
Exercises     -  
Anti-Dilution/Modification     9,668,867  
Forfeitures/cancellations     -  
Outstanding at March 31, 2020     14,713,127  
Weighted Average Price at March 31, 2020   $ 0.0217  

   

NOTE 7 – SUBSEQUENT EVENTS

 

In accordance with ASC 855, management reviewed all material events through May 15, 2020, for these financial statements and there are no material subsequent events to report, except as follows:

 

Conversion Notice

 

During April and May of 2020, we issued 59,094,721 shares of common stock for the conversion of $98,512 in convertible notes.

  

11 

 

  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2019, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

 

Forward-Looking Statement Notice

 

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

 

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

 

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

 

Overview

 

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments.

 

We currently conduct substantially all of our commercial operations through Creative Medical Technologies, Inc. (“CMT”) our wholly-owned subsidiary. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 12 locations in the United States and Europe.

 

We are currently focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, and commercializing our StemSpine® treatment for lower back pain. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our proprietary intellectual property.

 

Our principal executive offices are located at 3008 W Lupine, Phoenix, AZ 85029.  

 

During the first three months of 2020, we issued $168,300 in convertible notes with net proceeds of $145,000 to accredited investors.

 

During the three-month period ending March 31, 2020, we incurred interest expense of $49,714 arising from the third-party notes of $1,470,734.

      

12 

 

 

Plan of Operations

 

We commenced marketing disposable stem cell concentration kits for the CaverStem® erectile dysfunction treatment in the fourth quarter of 2017 and the FemCelz® female sexual dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of 2019. We also continued to make progress towards filing an Innovative New Drug (IND) application for the Amniostem universal donor stem cell to treat stroke and neurodegenerative conditions. For the next 12 months our plan of operations is to continue to expand the market for the CaverStem® and FemCelz® procedures, launch the StemSpine procedure, file an IND application on Amniostem and partner with leading researchers to initiate the Amniostem trial. As of March 31, 2020, we had approximately $38,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least May 2020. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

 

Results of Operations – For the Three-Month Period Ended March 31, 2020 and 2019

 

Gross Revenue. We generated $42,100 gross revenue for the three-month period ended March 31, 2020, in comparison with $50,800 for the comparable quarter a year ago. The decrease of $8,700 or 17% reflects the effects of the COVID-19 pandemic which caused the cessation of all elective procedures.

 

Cost of Goods Sold. We generated $14,196 cost of goods sold for the three-month period ended March 31, 2020, in comparison with $14,239 for the comparable quarter a year ago. The decrease of $43 or 0% is due to slightly lower gross margins as incentives were offered to new physician providers.

 

Gross Profit/(Loss). We generated $27,904 in gross profit for the three-month period ended March 31, 2020, in comparison with $36,561 for the comparable quarter a year ago. The decrease of $8,657 or 24% is due to the lower revenues and reduced margins referenced above.

 

General and Administrative Expenses. General and administrative expenses for the three-month period ended March 31, 2020, totaled $346,168, in comparison with $281,974, for the comparable quarter a year ago. The increase of $64,194, or 23% is primarily due to an increase of $30,000 in management fees and $41,282 in accounting and legal expenses.

 

Research and Development Expenses. There were no research and development expenses for the three-month period ended March 31, 2020, and for the comparable quarter a year ago.

 

Other Income / Expense. Other income for the three-month period ended March 31, 2020, totaled $4,077,516 in comparison with other expense of $546,667, for the comparable quarter a year ago. The increase of $4,624,183, or 846% is primarily due to a gain in the fair value of derivative liabilities of $4,400,739, a $131,319 reduction in interest expense and a loss during the three-month period ended March 31, 2019 of $357,292 associated with the extinguishment of convertible notes.

 

Net Loss. For the reasons stated above, our net income for the three-month period ended March 31, 2020, totaled $3,742,480 in comparison to a loss of $797,366, for the comparable quarter a year ago.

 

Liquidity and Capital Resources

 

Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED and FemCelz vaginal rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

  

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments.

 

For the next 12 months our plan of operations is to market our disposable kits and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

 

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

13 

 

 

Cash Flows

 

Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $195,321 for the three-month period ended March 31, 2020 in comparison to $273,015 for the comparable period a year ago, a decrease of $77,694 or 28%. The decrease in cash used in operations was primarily related to increases in accounts payable and monies owed to CMH.

  

Net Cash used in Investing Activities. There was no cash used in investing activities in the three-month periods ended March 31, 2020 and March 31, 2019, respectively.

 

Net Cash From Financing Activities. In the three-month period ended March 31, 2020, we raised $145,000 through the issuance of convertible debt, retired no convertible debt and did not pay any prepayment premiums on retired convertible notes. In the three-month period ended March 31, 2019, we raised $575,890 through the issuance of convertible debt, expended $168,300 to retire convertible debt, and paid $19,154 in prepayment premiums on the retired convertible notes. The $243,436 or 63% decrease in cash flows from financing activities were primarily related to reduced levels of financing and no loan repayments.

 

Basis of Presentation / Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.   As of March 31, 2020, the Company had $38,327 of available cash and a working capital deficit of $3,602,038. For the three-month period ended March 31, 2020, the Company had $42,100 in revenue, $335,036 in operating loss and used net cash for operating activities of $195,321. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of disclosure controls and procedures

 

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in internal control over financial reporting

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

14 

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. In April 2016, the Company entered into an agreement with a third party to perform banking services. The banking services did not materialize and thus the Company cancelled the agreement in June 2016. The Company and the third party are currently in a dispute as to fees under the agreement. The Company believes no consideration is due as the services were not performed. Any proposed litigation or equivalent will be vigorously defended for which the Company expects to prevail. As of the date of these financial statements the Company has not recorded a loss provision as the amount is not probable.

  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Convertible Notes/Debentures

 

During the three-months ended March 31, 2020, we issued convertible promissory notes in the face amount of $168,300 to multiple lenders for which we received proceeds of $150,278. The notes bear interest of 8% which would increase up to 24% in the event of default and have maturity dates in February 2021. The notes are convertible at rates ranging from 60% to 71% of either the average of the two lowest traded prices of our common stock during the prior 15 trading days preceding the conversion date or the average of the two lowest traded prices of our common stock during the prior 15 trading days preceding the conversion date. We have the option to redeem the notes, in whole or in part, on $168,300 of the face amount of the issued convertible promissory notes for premiums ranging from 0% to 125% of the outstanding principle and interest up to 180 days from the date of issuance. After 180 days the right of repayment expires. 

 

Item 6. Exhibits

 

SEC Ref. No.   Title of Document
31.1   Rule 13a-14(a) Certification by Principal Executive Officer
31.2   Rule 13a-14(a) Certification by Principal Financial Officer
32.1   Section 1350 Certification of Principal Executive Officer
32.2   Section 1350 Certification of Principal Financial Officer
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

15 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Creative Medical Technology Holdings, Inc.
     
Date: May 15, 2020 By    /s/ Timothy Warbington
    Timothy Warbington, Chief Executive Officer
    (Principal Executive Officer) 
     
Date: May 15, 2020 By /s/ Donald Dickerson
    Donald Dickerson, Chief Financial Officer
    (Principal Financial Officer)

  

16